# Alessandra Longhi

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/817365/alessandra-longhi-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91 5,170 37 71 g-index

94 5,775 3.4 4.83 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
91	Primary bone osteosarcoma in the pediatric age: state of the art. <i>Cancer Treatment Reviews</i> , <b>2006</b> , 32, 423-36	14.4	484
90	Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. <i>Cancer</i> , <b>2006</b> , 106, 1154-61	6.4	443
89	Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8845-52	2.2	343
88	Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 4016-27	2.2	327
87	Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 4-11	2.2	273
86	Giant cell tumor of the extremity: A review of 349 cases from a single institution. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36, 1-7	14.4	224
85	Phase II study of imatinib in advanced chordoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 914-20	2.2	189
84	Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. <i>Cancer</i> , <b>2003</b> , 97, 3068-75	6.4	163
83	Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 850-6	2.2	128
82	Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncolgica, 2006, 45, 469-75	3.2	115
81	Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. <i>Journal of Surgical Oncology</i> , <b>2007</b> , 96, 118-23	2.8	113
80	Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 2836-45	7.5	112
79	Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. <i>Acta Oncolgica</i> , <b>2005</b> , 44, 748-55	3.2	107
78	Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 2079-85	7.5	95
77	Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. <i>Cancer Research</i> , <b>2009</b> , 69, 2443-52	10.1	91
76	Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy. <i>Acta Orthopaedica</i> , <b>2003</b> , 74, 449-54		81
75	The role of surgical margins in treatment of EwingS sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 65, 766-72	4	79

## (2001-2003)

74	Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2003</b> , 25, 292-6	1.2	72
73	Neoadjuvant chemotherapy for extremity osteosarcomapreliminary results of the Rizzolis 4th study. <i>Acta Oncolgica</i> , <b>1998</b> , 37, 41-8	3.2	69
72	Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006). <i>Cancer</i> , <b>2012</b> , 118, 5050-9	6.4	65
71	Osteosarcoma in patients older than 65 years. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5368-73	2.2	65
70	Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 737-44	2.4	64
69	Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor Response. <i>Tumori</i> , <b>1999</b> , 85, 458-464	1.7	61
68	Height as a risk factor for osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2005</b> , 27, 314-8	1.2	59
67	Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2003</b> , 25, 845-53	1.2	54
66	Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. <i>Cancer</i> , <b>2006</b> , 106, 2701-6	6.4	53
65	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , <b>2018</b> , 104, 30-36	1.7	50
64	Palliative therapy for osteosarcoma. Expert Review of Anticancer Therapy, 2011, 11, 217-27	3.5	50
63	Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. <i>Cancer</i> , <b>2007</b> , 109, 780-6	6.4	50
62	Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. <i>Oncology Reports</i> , <b>2004</b> , 11, 111-20	3.5	50
61	Periosteal osteosarcoma: a single-institution experience. <i>Cancer</i> , <b>2011</b> , 117, 1731-5	6.4	49
60	Multimodal therapy for the treatment of nonmetastatic Ewing sarcoma of pelvis. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2003</b> , 25, 118-24	1.2	48
59	Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2005</b> , 27, 517-20	1.2	44
58	Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. <i>Oncology Reports</i> , <b>2002</b> , 9, 171-5	;3.5	44
57	Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,. <i>Clinical Orthopaedics and Related Research</i> , <b>2001</b> , 186-96	2.2	42

56	Treatment of nonmetastatic Ewing's sarcoma family tumors of the spine and sacrum: the experience from a single institution. <i>European Spine Journal</i> , <b>2009</b> , 18, 1091-5	2.7	41
55	Increased osteoclast activity is associated with aggressiveness of osteosarcoma. <i>International Journal of Oncology</i> , <b>2008</b> , 33, 1231-8	1	39
54	Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: the Rizzoli experience in 52 patients. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2006</b> , 77, 938-43	4.3	37
53	Pazopanib in relapsed osteosarcoma patients: report on 15 cases. <i>Acta Oncolgica</i> , <b>2019</b> , 58, 124-128	3.2	37
52	Primary high-grade osteosarcoma: comparison between preadolescent and older patients. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2005</b> , 27, 129-34	1.2	36
51	Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2006</b> , 28, 774-80	1.2	33
50	Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. <i>Oncotarget</i> , <b>2017</b> , 8, 111836-111846	3.3	32
49	High-grade osteosarcoma of the extremity: differences between localized and metastatic tumors at presentation. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2002</b> , 24, 27-30	1.2	31
48	Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results. <i>Tumori</i> , <b>2018</b> , 104, 344-351	1.7	30
47	Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. <i>Oncology Reports</i> , <b>2003</b> , 10, 151-5	3.5	30
46	Predictive factors of histologic response to primary chemotherapy in patients with Ewing sarcoma. Journal of Pediatric Hematology/Oncology, <b>2007</b> , 29, 364-8	1.2	26
45	Late relapse in osteosarcoma. Journal of Pediatric Hematology/Oncology, 2006, 28, 418-22	1.2	26
44	Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. <i>Cancer</i> , <b>2000</b> , 89, 1961-5	6.4	26
43	Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2007</b> , 78, 377-84	4.3	25
42	Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 11502-11502	2.2	22
41	A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2014</b> , 210198	2.3	20
40	Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. <i>Oncology Reports</i> , <b>2001</b> , 8, 883-8	3.5	20
39	Delay in Diagnosis of High-Grade Osteosarcoma of the Extremities. Has it any Effect on the Stage of Disease?. <i>Tumori</i> , <b>2000</b> , 86, 204-206	1.7	19

## (2016-2001)

38	Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases. <i>Acta Orthopaedica</i> , <b>2001</b> , 72, 167-72		19
37	Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. <i>Anticancer Research</i> , <b>2015</b> , 35, 5581-6	2.3	18
36	Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 55, 652-4	3	17
35	Predictive factors of histological response to primary chemotherapy in EwingS sarcoma. <i>Acta Oncolgica</i> , <b>1998</b> , 37, 671-6	3.2	17
34	Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 67, 505-11	4	15
33	The role of 18F-FDG PET/CT in soft tissue sarcoma. <i>Nuclear Medicine Communications</i> , <b>2019</b> , 40, 626-63	1 1.6	15
32	Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. <i>Oncology Reports</i> , <b>2003</b> , 10, 851-7	3.5	15
31	No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma. <i>Anti-Cancer Drugs</i> , <b>2006</b> , 17, 411-5	2.4	14
30	Ewing's sarcoma family tumors of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 93, 383-7	5.3	13
29	Simultaneous osteosarcoma lung metastasis and second primary lung cancer. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2004</b> , 26, 457-61	1.2	13
28	Osteosarcoma follow-up: chest X-ray or computed tomography?. Clinical Sarcoma Research, 2017, 7, 3	2.5	12
27	Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 2617-2624	7.4	12
26	Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27792	3	11
25	Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27653	3	9
24	High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. <i>Oncology</i> , <b>1991</b> , 48, 1-6	3.6	9
23	Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 441-445	3.5	8
22	A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. <i>European Journal of Integrative Medicine</i> , <b>2009</b> , 1, 27-33	1.7	8
21	Ewing sarcoma in patients over 40 years of age: a prospective analysis of 31 patients treated at a single institution. <i>Tumori</i> , <b>2016</b> , 102, 481-487	1.7	8

20	Exploring Metabolic Adaptations to the Acidic Microenvironment of Osteosarcoma Cells Unveils Sphingosine 1-Phosphate as a Valuable Therapeutic Target. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
19	. Cancer, <b>2000</b> , 89, 1961-1965	6.4	6
18	Outcome of lung metastases due to bone giant cell tumor initially managed with observation. <i>Journal of Orthopaedic Surgery and Research</i> , <b>2020</b> , 15, 510	2.8	5
17	Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 591-599	4.4	5
16	Spontaneous regression of lung metastasis from osteosarcoma: a case report. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2008</b> , 30, 90-2	1.2	4
15	Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. <i>Sarcoma</i> , <b>2020</b> , 2020, 8260730	3.1	3
14	The role of chemotherapy in the treatment of bone and soft tissue sarcomas. <i>Orthopaedics and Trauma</i> , <b>2005</b> , 19, 119-126		3
13	The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
12	Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. <i>Oncology Reports</i> , <b>2003</b> , 10, 151	3.5	2
11	A comment and update on "Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival?". <i>European Journal of Cancer</i> , <b>2003</b> , 39, 548-9	7.5	2
10	Relative Validity of an Italian EPIC Food Frequency Questionnaire for Dietary Factors in Children and Adolescents. A Rizzoli Orthopedic Institute Study. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	2
9	Histological response to neoadjuvant chemotherapy in localized Ewing sarcoma of the bone: A retrospective analysis of available scoring tools. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1778-	1783	2
8	Salivary gland second cancer after bone sarcoma treatment. <i>European Journal of Orthopaedic Surgery and Traumatology</i> , <b>2015</b> , 25, 1201-4	2.2	1
7	Maternal and neonatal outcomes in pregnancies complicated by bone and soft-tissue tumors. <i>Obstetrics and Gynecology</i> , <b>2005</b> , 105, 447; author reply 447-8	4.9	1
6	Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
5	Long term results in osteosarcoma patients treated with Viscum album Fermentatum P versus Etoposide as maintenance therapy after second relapse. <i>Phytomedicine</i> , <b>2019</b> , 61, 10-11	6.5	1
4	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2) <i>Cancer</i> , <b>2022</b> ,	6.4	1
3	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10517-10517	2.2	O

#### LIST OF PUBLICATIONS

Predictors of lung recurrence and disease-specific mortality after pulmonary metastasectomy for soft tissue sarcoma. *Surgical Oncology*, **2021**, 37, 101532

2.5 0

Advances in treatment for tenosynovial giant cell tumors. Expert Opinion on Orphan Drugs, 2018, 6, 753-757